ERBB3 V104M

CI-VAR-00004435Explore in graph →ClinVar 376410 CIViC 701 rs1057519893

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm2
ERBB3 V104M	(oncogenic)	Oncogenic	D	Supports Oncogenicity	2	submitted	EID9669 Somatic mutations in ERBB3 were identified in ~11% of gastric and colon cancers. Relative to wild-type ERBB3, the V104M mutation in the presence of ERBB2 resulted in increased anchorage independent gr… (full text at CIViC) PMID 23680147 · Jaiswal et al., 2013 · Open in CIViC	civic
ERBB3 V104M	Duligotuzumab + Lapatinib + Pertuzumab + TrastuzumabSubstitutes	Predictive	D	Supports Sensitivity Response	2	submitted	EID9670 Somatic mutations in ERBB3 were identified in ~11% of gastric and colon cancers. Relative to wild-type ERBB3, the V104M mutation in the presence of ERBB2 resulted in increased anchorage independent gr… (full text at CIViC)

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376410	Pathogenic	no assertion criteria provided	0	Malignant tumor of urinary bladder; Neoplasm	somatic	2	—	clinvar

Transitional Cell Carcinoma1
ERBB3 V104M	Afatinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID1746 In this phase II trial, patients with metastatic platinum-refractory urothelial carcinoma (UC) received afatinib (40 mg/day). Among the 21 tumors, five of six patients (83.3%) with ERBB2 (HER2) and/or… (full text at CIViC) PMID 27044931 · Choudhury et al., 2016 · Open in CIViC	civic

Unmapped disease1unmapped disease
ERBB3 V104M	(functional)	Functional	D	Supports Gain Of Function	2	submitted	EID9668 Somatic mutations in ERBB3 were identified in ~11% of gastric and colon cancers. Relative to wild-type ERBB3, the V104M mutation in the presence of ERBB2 resulted in increased anchorage independent gr… (full text at CIViC) PMID 23680147 · Jaiswal et al., 2013 · Open in CIViC	civic